Jul 15, 2020 · Minimal residual disease (MRD) is common in patients with blood cancers, such as leukemia, lymphoma and multiple myeloma. But what does this mean for patients and their need for additional cancer treatment? Ghayas Issa, M.D., explains.

Mar 13, 2023 · What is molecular residual disease (MRD)? Molecular residual disease (MRD), also called minimal or measurable residual disease, refers to the presence of a very small number of cancer-derived molecules (such as DNA or protein) that remain in circulation during or after cancer treatment.

Minimal residual disease (MRD) is termed as the small numbers of remnant tumor cells in a subset of patients with tumors. Liquid biopsy is increasingly used for the detection of MRD, illustrating the potential of MRD detection to provide more …

Apr 18, 2024 · In the context of cancer, MRD-testing attempts to quantify residual cancer cells when the cancer is no longer detectable by conventional methods including blood tests, biopsy or...

Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress.

Minimal residual disease (MRD), also known as Molecular residual disease, is the medical condition in which small number of cancer cells persist in a patient either during or after treatment when the patient is in remission and that cannot be detected with current medical imaging or routine screening options (occult stage of cancer progression).

Current liquid biopsy assays are able to detect circulating tumor DNA (ctDNA) levels when tumor burden is high, but are not sensitive enough to detect minimal residual disease (MRD) when...

Nov 28, 2024 · Liquid biopsy, or the analysis of tumour-derived or tumour-induced cells or cellular products in the blood or other body fluids, has opened a new diagnostic avenue to detect and monitor MRD....

Dec 13, 2024 · Circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive tool for detecting minimal residual disease (MRD) in colorectal cancer (CRC) patients. This enables dynamic risk stratification, earlier recurrence detection and optimized post-surgical treatment.

Nov 21, 2024 · Measurable or minimal residual disease (MRD) testing is used to see if the cancer treatment is working and to guide further treatment plans. MRD testing is mainly used in blood cancers (leukemia, lymphoma and myeloma), but is being studied in other cancers.